2017 The Cell Biology of Megakaryocytes & Platelets Gordon Research Conference & Gordon Research Seminar

2017 巨核细胞的细胞生物学

• 批准号: 9248106
• 负责人: Wolfgang Bergmeier
• 金额: $ 1.87万
• 依托单位: GORDON RESEARCH CONFERENCES
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-01-01 至 2017-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9248106
• 关键词: Academia; Address; Affect; Apoptosis; Area; Biology; Blood Cells; Blood Platelet Disorders; Blood Platelets; Blood coagulation; Cardiovascular Diseases; Cells; Cellular biology; Clinical; Coffee; Collaborations; Coupled; Data; Development; Diagnosis; Disease; Fostering; Future; Genetic; Genomic approach; Goals; Gray unit of radiation dose; Growth; Hematological Disease; Hemorrhage; Hemostatic function; Immunity; Infection; Inflammation; International; Knowledge; Lesion; Link; Longevity; Lymphatic; Malignant Neoplasms; Mediating; Mediator of activation protein; Medical Genetics; Medicine; Megakaryocytes; Mentors; Mission; Mutation; Myeloproliferative disease; Myocardial Infarction; Nature; Neoplasm Metastasis; Outcome; Pathologic; Play; Prevention; Process; Production; Publications; Recording of previous events; Regulation; Research; Research Personnel; Role; STK6 gene; Seminal; Stem Cell Development; Stem cells; Stroke; Syndrome; Technology; Therapeutic; Thrombosis; Thrombus; Time; Ursidae Family; Work; Wound Healing; career; cell type; design; exome sequencing; experience; genome wide association study; genomic biomarker; improved; inhibitor/antagonist; leukemia; meetings; novel; novel therapeutics; professor; programs; receptor; symposium; therapeutic target; tumor

PROJECT SUMMARY / ABSTRACT The biennial Gordon Research Conference (GRC) and Gordon Research Seminar (GRS) on the Cell Biology of Megakaryocytes and Platelets brings together current leaders, junior investigators and trainees working on the development and disorders of the megakaryocyte lineage. It is the premier international meeting in the field. The ongoing, long-term scientific mission is to bridge the gap between researchers working on different aspects of the lineage, i.e. stem cells, megakaryocytes and platelets. This mission is more relevant than ever, as the interdependence between each cell type becomes increasingly clear, e.g. the role of megakaryocytes in stem cell development, and the impact of inflammation on megakaryocyte growth and platelet production. The overarching, aim of the GRC is to allow current and emerging leaders of the field to communicate unpublished data, thereby educating colleagues, promoting discussions and fostering collaborations. Specifically, the aims are to:1. Highlight the extraordinary progress being made in congenital platelet disorders. In 2000, the causative lesion was known for ~5% of these conditions. This is now more than 50%. The impact this knowledge is having on diagnosis, treatment and the opening up of novel therapeutic possibilities will be discussed.2. Disseminate the latest unpublished research linking the lineage to immunity and inflammation. It is increasingly apparent that platelets can promote inflammation, and that inflammation and infection can impact on hemostasis and trigger hemorrhage. This suggests a range of new therapeutic entry points that will be vigorously explored. 3. Promote the expanding field of platelets in cancer. This includes the role platelets play in mediating tumor metastasis, and the link between cancer-associated inflammation, elevated platelet production, and thrombosis. Despite decades of research, only now are some of the potential therapeutic entry points beginning to emerge. To achieve these aims, the 2017 GRC has made the following commitments: 1. In the earlier iterations of this meeting, sessions focused on platelets or megakaryocytes, and the meeting was essentially divided into two halves. For GRC 2017, the program intermixes sessions on megakaryocytes or platelets with sessions dealing with processes or diseases affecting/involving the lineage more broadly. 2. In 2017 we will be compressing the coffee breaks and trimming keynote speaker times to allow 12 talks to be selected from abstracts. Senior investigators will be kept absolutely to time, and the abstract talks will be intermixed with invited speakers so that attendance is maximized for junior investigators. 3. Multidisciplinarity will be emphasized, e.g. the session on the various approaches and technologies that are being brought to bear on congenital platelet disorders, including mapping, exome sequencing, and GWAS. 4. The therapeutic potential of the field in multiple areas will be tackled, with talks on c-Mpl mutations in myeloproliferative neoplasms, agents such as AURKA inhibitors in leukemia, and PI3K inhibitors in thrombosis.

项目摘要 /摘要 双年展戈登研究会议（GRC）和戈登研究研讨会（GRS）关于细胞生物学 巨核细胞和血小板汇集了当前的领导者，初级调查员和受训者 巨核细胞谱系的发展和疾病。这是国际首屈一指的会议 场地。持续的长期科学任务是弥合研究不同的研究人员的差距 谱系的各个方面，即干细胞，巨核细胞和血小板。这个任务比以往任何时候都更有意义 随着每种细胞类型之间的相互依赖性变得越来越清晰，例如巨核细胞在 干细胞的发育以及炎症对巨核细胞生长和血小板产生的影响。 GRC的总体目的是允许该领域的当前和新兴领导者进行交流 未发表的数据，从而对同事进行教育，促进讨论并促进合作。 具体而言，目的是：1。强调先天性血小板疾病的非凡进展。 在2000年，因这些条件中约5％而闻名。现在，这超过50％。影响 这些知识是关于诊断，治疗和新型治疗可能性开放的知识 讨论了2。传播最新的未发表研究，将谱系与免疫力和炎症联系起来。它 越来越明显的是，血小板可以促进炎症，并且炎症和感染可以 影响止血并触发出血。这表明一系列新的治疗入口点将 大力探索。 3。促进癌症中血小板的扩大领域。这包括血小板在介导肿瘤中扮演的角色 转移以及与癌症相关的炎症，血小板产生升高和 血栓形成。尽管进行了数十年的研究，但现在才有一些潜在的治疗入口 开始出现。为了实现这些目标，2017年GRC做出了以下承诺： 1。在这次会议的较早迭代中，会议的重点是血小板或巨核细胞和会议 本质上分为两半。对于GRC 2017，该程序在巨核细胞上进行混合会话 或血小板的疗程或疾病涉及谱系的过程或疾病更广泛。 2。在2017年，我们将压缩咖啡休息时间和修剪主题演讲者时间，以允许12次谈判 从摘要中选择。高级调查人员将绝对保持时间，抽象会谈将是 与受邀演讲者互混合，以便为初级调查人员最大化出勤率。 3。将强调多学科，例如有关各种方法和技术的会议 因先天性血小板疾病而被带来，包括映射，外显着测序和GWAS。 4。将解决该领域在多个领域的治疗潜力，并进行有关C-MPL突变的谈判 骨髓增生性肿瘤，白血病中的Aurka抑制剂和血栓形成中的PI3K抑制剂。